Abstract:Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains the leading cause of cancer deaths. Much progress has been made to treat NSCLC, however, only limited patients can benefit from current treatments. Thus, more efforts are needed to pursue novel molecular modalities for NSCLC treatment. It was demonstrated that pseudo-natural products (PNP) are a critical source for antitumor drug discovery. Herein, we describe a CH activation protocol for the expedient construction of a focused library utilizing the PNP rational design strategy. This protocol features a rhodium-catalyzed CH activation/ [4+2] annulation reaction between N-OAc-indole-2-carboxamide and alkynyl quinols, enabling facile access to diverse quinol substituted β-carboline derivatives (31 examples). The anticancer activities were assessed in vitro against NSCLC cell line A549, yielding a potent antiproliferative β-carboline derivative (8r) with an IC50 value of 0.8 ± 0.1 µM. Further investigation revealed that this compound could decrease the expression of Caspase 3, and increase the expression of autophagic protein Cyclin B1, thus markedly inducing autophagy and apoptosis. Mechanistic study suggested that 8r could be a potent anti-NSCLC agent through the AKT/mTOR signaling pathway in A549 cells. Moreover, the anticancer activities were also assessed against three other cancer cell lines, and 8r exhibits a broader inhibitory effect on cell proliferation in all cancer cell lines tested. These results indicated that carboline-based PNPs show great potential to induce cell autophagy and apoptosis, which serve as good leads for further drug discovery.

Design, Synthesis, and Biological Evaluation of Novel Γ-Carboline Ketones As Anticancer Agents

Design, Synthesis, and Biological Evaluation of Novel N-γ-carboline Arylsulfonamides As Anticancer Agents.

Design and One-Pot Synthesis of New 7-Acyl Camptothecin Derivatives As Potent Cytotoxic Agents

Selective and effective anticancer agents: Synthesis, biological evaluation and structure–activity relationships of novel carbazole derivatives

Design, Synthesis and Biological Activity Evaluation of β-Carboline Derivatives Containing Nitrogen Heterocycles

Synthesis and biological evaluation of a novel class of beta-carboline derivatives

Synthesis And Evaluation Of New Podophyllotoxin Derivatives With In Vitro Anticancer Activity

Design, Synthesis, and Biological Evaluation of 4-Aryl-9h-carbazoles As Tubulin Polymerization Inhibitors with Potent Anticancer Activities

Discovery of Novel Heteroarylmethylcarbamodithioates As Potent Anticancer Agents: Synthesis, Structure-Activity Relationship Analysis and Biological Evaluation.

Synthesis and Biological Evaluation of a Novel Class of Coumarin Derivatives.

Structure-Activity Relationship Study of New Carbazole Sulfonamide Derivatives as Anticancer Agents with Dual-target Mechanism

Design, synthesis, and biological evaluation of 4-aryl-9 H -carbazoles as tubulin polymerization inhibitors with potent anticancer activities

Design, Synthesis, and Biological Evaluation of Novel N-Acylhydrazone Bond Linked Heterobivalent β-Carbolines as Potential Anticancer Agents

Design, Synthesis and Biological Evaluation of a Series of New Resveratrol Analogues As Potential Anti-Cancer Agents

Synthesis And In Vitro Cytotoxic Evaluation Of Novel -(3,4,5-Trimethoxyphenyl)Pyridin-2()-One Derivatives

Design, synthesis, and quantitative structure–activity relationship of cytotoxic γ-carboline derivatives

Design, synthesis and anticancer activity of β-carboline based pseudo-natural products by inhibiting AKT/mTOR signaling pathway

Synthesis and Biological Evaluation of Novel Pyrazoline Derivatives Containing Indole Skeleton As Anti-Cancer Agents Targeting Topoisomerase II.

Design, Synthesis, and Antitumor Activity of Β-Carboline- Benzimidazole Hybrids

Design, Synthesis and Biological Evaluation of Novel Diarylpyridine Derivatives As Tubulin Polymerisation Inhibitors

Synthesis, Biological Evaluation, and Molecular Docking Studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline Derivatives As Novel Anticancer Agents